Board
Dr. Irwin Scher
Chairman
Dr. Scher is certified by the American Board of Rheumatology and American Board of Internal Medicine. He received his M.D. from Albert Einstein College of Medicine in New York and completed residencies at Presbyterian Hospital, University of Pittsburgh Medical Center, and Albert Einstein College of Medicine. Dr. Scher holds a B.S. in Chemistry from the State University of New York at Albany.​
​
Following his medical training he joined the Navy, eventually attaining a position as Captain USN Medical Corps at the Bethesda Naval Medical Complex. While there, Dr. Scher served as Professor of Medicine, Uniformed Services University, and Head, Immunology Branch, Naval Medical Research Institute. Following that, he spent 22 years in various positions at Merck, Astra/Merck, Astra Zeneca, and as Consultant to the Chief Executive Officer at Merck KGaA. From 2005-2011, Dr. Scher was the President and Chief Executive Officer of Biosynexus, a biotechnology company focused on treating and preventing Staphylococcal infections.
​
Dr. Scher is Chairman and a Founder of Opertech and is chairman of the board of VaxImmune and a board member of the of Score Pharmaceuticals. He is currently actively involved as an angel investor in several biologically focused startup companies.
Steven Feder
Director​
Steven Feder is General Counsel & Corporate Secretary at CompoSecure. He is also responsible for regulatory compliance and supports the Board and its committees. Steve has previously been General Counsel of other publicly-traded companies and was a partner at several prestigious law firms. Steve founded the legal consulting firm, GenCounsel, LLC, in 2009. Over the course of his three decade career, Steve has helped numerous companies navigate the legal challenges associated with growing their businesses, including capital raising, compliance, mergers and acquisitions, divestitures, public company and securities matters, joint ventures, contracts, litigation, IP protection, employment and compensation matters.
Steve received his law degree from Temple University School of Law and his undergraduate degree in teaching English from Temple University’s College of Education.
​
​
Evan Tarte
Director​
Evan Tarte is a principal at Tarte Family Office and is currently involved in sourcing and executing lower middle market buyouts. Previously, he was an investment professional at EagleTree Capital ($6B AUM) where he focused on middle market investment opportunities in the business services and specialty industrial sectors. Prior to EagleTree, Evan was the COO of DiversityInc (DBA Fair360), a middle market DEI-focused data company ($8M EBITDA). Evan began his career as an associate at Hersha Hospitality Management ($2B AUM) and an investment banking analyst at Lazard.
Evan received his A.B. in Economics (Hons.) and History (Hons.) from Georgetown University (magna cum laude), his M.Phil in Economic History from the University of Cambridge (first class), and his J.D. from Harvard Law School, where he was the John M. Olin Fellow in Empirical Law and Finance.
​